Liewei Wang, M.D., Ph.D.
Triple negative breast cancer (TNBC) is one of three subtypes that makes up to 15 – 20% of breast cancer cases. This disease is very aggressive with the highest recurrence rate in the first five years compared to ER+ or HER2 breast cancers. Current treatment is limited to cytotoxic chemotherapy due to the lack of targeted therapy available for clinical use. Thus, there is a great need to identify alternative treatments for this disease.
Metformin, an anti-type 2 diabetic drug, has been reported to have an anticancer effect in different cancers including breast cancer. However, the mechanism of anticancer action is unclear. Dr. Wang and her laboratory team took a pharmacogenomics approach using a genetically diverse lymphoblastoid cell line model to identify potential novel genes, SNPs, or methylation loci that may influence metformin anticancer response. Using this approach, we identified CDC25B to modulate metformin anticancer response in TNBC. Currently, my thesis work is focused on investigating the mechanism of how CDC25B regulates metformin anticancer response in this disease.
July 26, 2017